MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (739)	9/24/2003 10:48:23 AM
From: Icebrg	Read Replies (1) of 2240

GENMAB INITIATES PHASE I/II TRIAL USING HUMAX-EGFR TO TREAT CANCER Summary: Genmab initiates Phase I/II trial using HuMax-EGFr to treat head and neck cancer. Copenhagen, Denmark; September 24, 2003 – Genmab A/S (CSE: GEN) announced today it has initiated a Phase I/II trial using HuMax-EGFr to treat patients suffering from head and neck cancer. About the trial The trial is expected to include a maximum of 36 patients. Patients will receive a single dose of HuMax-EGFr from one of six dose groups (0.15, 0.5, 1, 2, 4 or 8 mg/kg) and will be followed for four weeks before receiving four further doses of HuMax-EGFr at weekly intervals. Patients who received the 8mg/kg in single dose will receive 4mg/kg during the subsequent four week dosing period.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next